Company profile

AstraZeneca

Biopharmaceuticals · Cambridge, United Kingdom · astrazeneca.com

AstraZeneca is a global, science-led biopharmaceutical company focused on discovering, developing, commercializing prescription medicines across oncology, bio-pharmaceuticals, rare disease. Current strategy centers on Ambition 2030, pipeline expansion, R&D productivity, scaled manufacturing and supply chain execution, with heavier use of data, AI, digital operations.

Strategic priorities

Pipeline and launch growth

The company says it aims to launch at least 20 new medicines by 2030 and continue sustained revenue growth.

Annual report states Ambition 2030 targets at least 20 new medicines and $80 billion in total revenue, with 2025 reporting 38 pipeline progression events and 97 regulatory events.

Annual report 2025

R&D transformation

Management is explicitly prioritizing faster research and stronger development productivity.

Annual report lists strategic focus areas that include delivering the next wave of pipeline innovation, accelerating therapeutic modalities, transforming R&D ways of working.

Annual report 2025

World class supply chains

Operations modernization is a named strategic priority, not just a support function.

Annual report lists realising world class supply chains as a strategic focus area, while a 2026 supply chain IT role calls for a Digital, Data and AI strategy and cloud aligned analytics ecosystem.

Director, IT Business Partner Global Supply Chain at AstraZeneca

Manufacturing digitization

The company is investing in autonomous and data driven manufacturing capabilities.

A 2026 Singapore role says the new biologics campus will use modern digital and automation infrastructure, autonomous manufacturing, AI, predictive capabilities, real time decision making.

Digital Lead at AstraZeneca

AI program

AstraZeneca publicly describes AI as a core capability across research, development, manufacturing, supply chain, digital health. Its Enterprise AI pages say the company is building an AI empowered organization with a 100% workforce AI proficiency commitment, while 2026 roles describe an Enterprise AI Unit, R&D AI transformation, multimodal AI, foundation models, generative AI operations, AI enabled decision support. Public postings also show AI use in trial optimization, supply chain forecasting, autonomous manufacturing, clinical data science.

Technology posture

AstraZeneca is moving toward a data heavy, cloud aligned, AI enabled operating model across R&D, operations, digital health.

Cloud

4/5

5/5

Data

5/5

Public roles emphasize cloud platforms, data foundations, analytics, digital twins, CI/CD, infrastructure as code, responsible AI governance.

Technology vendor categories

Cloud

AWS, cloud infrastructure and platform services are referenced in public role descriptions; n/a for a full enterprise inventory.

Data

SAS, Veeva, LIMS and historian platform providers, data platform providers, analytics vendors are referenced in public roles and press coverage.

OpenAI, Anthropic, other foundation model platforms are referenced in a 2026 cloud operations role; GenAI tooling vendors are also named in that role.

ERP

Enterprise systems and ERP are referenced in manufacturing and digital roles; specific ERP vendor names are not publicly confirmed in the sources reviewed.

Security

Cybersecurity, validation, audit readiness, data governance vendors or service partners are referenced, but specific named vendors are limited in the sources reviewed.

DevOps

CI/CD, infrastructure as code, containerization, observability, MLOps tool vendors are referenced in AI operations roles; specific vendor mix is not fully disclosed publicly.

Recent developments

Sources

Get the full sourced brief on AstraZeneca

This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.

Generate a full brief

Your first brief is free, no card required.

Evidence confidence 87/100. Generated 2026-07-03 from public sources.